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Background:  Two  inﬂuenza  B lineages  have  been  co-circulating  since  the 1980s,  and  because  inactivated
trivalent  inﬂuenza  vaccine  (TIV)  contains  only  one  B strain,  it provides  little/no  protection  against  the
alternate  B-lineage.  We  assessed  a candidate  inactivated  quadrivalent  inﬂuenza  vaccine  (QIV)  containing
both  B  lineages  versus  TIV  in healthy  adults.
Methods: Subjects  received  one  dose  of  QIV  (lot 1, 2,  or  3) or one  of  two  TIVs  (B strain  from  Victoria  or
Yamagata  lineage);  randomization  was  2:2:2:1:1.  Hemagglutination-inhibition  assays  were  performed
21-days  post-vaccination;  superiority  of  QIV  versus  TIV  for the alternate  B-lineage  was  demonstrated  if
the  95%  conﬁdence  interval  (CI)  lower  limit  for  the  GMT  ratio  was  ≥1.5,  and non-inferiority  against  the
shared  strains  was  demonstrated  if the  95% CI  upper  limit  for the  GMT  ratio  was ≤1.5.  Reactogenicity  andictoria  lineage
amagata lineage
safety  were  assessed  during  the post-vaccination  period.  NCT01196975.
Results: Immunogenicity  of  QIV  lots  was  consistent,  QIV  was  superior  to TIV  for the  alternate  B-lineage
strain,  and QIV  was  non-inferior  versus  TIVs  for shared  strains  (A/H1N1,  A/H3N2,  B-strain).  Reactogenicity
and  safety  proﬁle  of  the QIV was  consistent  with  seasonal  inﬂuenza  vaccines.
Conclusion: QIV  provided  superior  immunogenicity  for the  added  B strain  without  affecting  the  antibody
response  to  the TIV strains,  and  without  compromising  safety.Abbreviations: TIV, inactivated trivalent inﬂuenza vaccine; QIV, inactivated
uadrivalent  inﬂuenza vaccine; TIV-Vic, TIV-B Victoria; TIV-Yam, TIV-B Yamagata;
I,  conﬁdence interval; HA, Hemagglutinin; HI, Hemagglutination inhibition; GMT,
eometric mean titer; SCR, Seroconversion rate; SCF, seroconversion factor; SPR,
eroprotection rate; AEs, adverse events; MAEs, medically attended events; SAEs,
erious adverse events; WHO, World Health Organization; ATP, According to pro-
ocol; CBER, Center for Biologics Evaluation and Research; CDC, Center for Disease
ontrol and Prevention.
 This  is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
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1. Introduction
Inﬂuenza is a major public health threat, and in the US,
seasonal inﬂuenza epidemics account for more than 200,000
hospitalizations and more than 30,000 deaths annually [1,2].
Although inﬂuenza B is less of a public health burden than inﬂuenza
A/H3N2 [2], inﬂuenza B viruses cause seasonal epidemics in adults
every two to four years [3], and based on data across four seasons,
clinical symptoms and hospital admission rates were similar
in patients infected with inﬂuenza B compared with inﬂuenza
A [4].Two antigenically-distinct inﬂuenza B lineages (B/Victoria and
B/Yamagata) emerged in the 1980s, and have co-circulated in the
US since 2000. However, seasonal inﬂuenza vaccines have con-
ventionally been trivalent, including only one B lineage, meaning
reserved.
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hat mismatch between the circulating inﬂuenza B virus and
he vaccine strain is common. For example, between 2000 and
010 in the US, the trivalent vaccine was mismatched for the
irculating inﬂuenza B strain in six of ten seasons [5], resulting
n reduced vaccine effectiveness in the mismatched years [6,7].
he huge impact of seasonal inﬂuenza vaccine mismatch with
he circulating B lineage was demonstrated in Taiwan during
he 2011–2012 season when the trivalent vaccine contained a
/Victoria lineage strain whereas the predominant virus was an
nﬂuenza B/Yamagata strain; based on laboratory-conﬁrmed cases
f inﬂuenza in vaccinated outpatients identiﬁed over 6 months
uring the peak season, a test-negative case-control analysis
howed that the adjusted vaccine effectiveness against inﬂuenza
 was 54% (95% conﬁdence interval: 3, 78), yet against inﬂuenza B
as −66% (95% conﬁdence interval: −132, −18) [8].
The inclusion of an inﬂuenza B strain from both the Victoria
nd Yamagata lineages in a quadrivalent vaccine could improve
rotection against inﬂuenza B, and could reduce the burden of sea-
onal inﬂuenza illness, hospitalization, and death [9]. As such, for
he ﬁrst time, the World Health Organization (WHO) recommended
 strains from both lineages for use in vaccines for the 2012–2013
eason in the Northern Hemisphere [10]. There are currently four
uadrivalent vaccines approved in the US, produced by three manu-
acturers (MedImmune, Sanoﬁ Pasteur, GlaxoSmithKline Vaccines)
11]. A live attenuated quadrivalent vaccine has been assessed in
hildren aged 2–17 years [12], and in adults aged 18–49 years
13], and in each study was found to provide non-inferior immune
esponses compared with a live attenuated trivalent inﬂuenza
accine. Inactivated quadrivalent inﬂuenza vaccines have been
howed to be immunogenic for all four vaccine strains, with supe-
ior or non-inferior immunogenicity for the additional B strain
ompared with TIV, without interfering with antibody responses
o the three shared strains in children aged 3–17 years [14,15], and
n adults [16,17].
In  this Phase III, double-blind, randomized study we  assessed the
mmunogenicity, reactogenicity, and safety of a candidate inactiv-
ted quadrivalent split virion inﬂuenza vaccine (QIV). The aim of the
tudy was to evaluate the immunological consistency of three QIV
ots, the superiority of antibody responses against the B strains in
he QIV versus TIVs containing the alternate B lineage, and the non-
nferior immunogenicity for QIV and TIV against shared inﬂuenza
 and B strains.
.  Methods
This Phase III, randomized, double-blind study compared the
mmunogenicity of QIV and TIV in adults. Reactogenicity and safety
as also assessed. The study was conducted in Canada, Mexico, and
he US. Eligible subjects were aged ≥18 years, were in stable health,
nd had not received any non-registered drug or vaccine within 30
ays or any investigational or approved inﬂuenza vaccine within
ix months of the ﬁrst visit. All subjects provided written informed
onsent.
The study protocol, any amendments, informed consent and
ther information requiring pre-approval were reviewed and
pproved by national, regional, or investigational center Institu-
ional Review Boards. The study was conducted in accordance with
ood Clinical Practice, the principles of the Declaration of Helsinki,
nd all regulatory requirements. Clintrials.gov NCT01196975.
.1.  Vaccines and randomizationSubjects  were scheduled to receive a single dose of either a
icensed seasonal TIV (FluLavalTM, GlaxoSmithKline Vaccines) or
 candidate QIV. All vaccines contained 15 g of hemagglutinin2 (2014) 1480–1487 1481
antigen (HA) of inﬂuenza A/H1N1 (A/California/7/2009) and
A/H3N2 (A/Victoria/210/2009), as recommended by WHO  for
the 2010/11 inﬂuenza season. The TIV contained 15 g HA of an
inﬂuenza B strain from the Victoria lineage (B/Brisbane/60/2008
[B lineage recommended for 2010/11 season by WHO]) or the
Yamagata lineage (B/Florida/4/2006) and the QIV contained 15 g
HA of both inﬂuenza B strains. The TIVs and QIV were given as
a 0.5 mL  dose; the TIVs contained 0.50 g thimerosal and the
QIV was  thimerosal-free. All vaccines were manufactured by
GlaxoSmithKline (GSK) Biologicals in Quebec, Canada.
Randomization was performed by the study sponsor using a
blocking scheme, and treatment allocation at the investigator site
was performed using a central randomization system on the inter-
net. Subjects were randomized 2:2:2:1:1 to receive QIV (lot 1, 2, or
3), TIV-B Victoria (TIV-Vic) or TIV-B Yamagata (TIV-Yam). Groups
had an equal distribution of subjects aged 18–64 years versus
≥65 years and a minimization algorithm was used to account for
country, and inﬂuenza vaccination in the previous season. Subjects
received one dose of vaccine in the deltoid of the non-dominant
arm. All personnel and subjects were blind to the vaccine allocation.
2.2. Assessments and objectives
2.2.1.  Immunogenicity
Blood was  collected for serological testing on or just before
vaccination (Day 0) and then 21 and 180 (sub-cohort) days post-
vaccination (Day 21, and Day 180, respectively). Hemagglutination
inhibition (HI) antibody titers against the vaccine strains were
assessed at GlaxoSmithKline Vaccines central laboratory using val-
idated assay methods as previously described [18].
The  primary objective was  to assess the lot-to-lot consistency of
three QIV lots based on GMTs at Day 21 post-vaccination. Secondary
objectives were to evaluate: the superiority of GMTs at Day 21 for
QIV versus TIV-Vic against the Yamagata B strain, and QIV versus
TIV-Yam against the Victoria B strain (i.e. B strains absent from each
TIV); and the non-inferiority of GMTs at Day 21 for QIV versus TIV-
Vic + TIV-Yam against all four strains, QIV versus TIV-Vic against
the Victoria B strain, and QIV versus TIV-Yam against the Yama-
gata B strain (i.e. shared strains). Immunogenicity was described
at Day 0, 21, and 180 (sub-cohort) including GMTs, seroprotection
rate (SPR; proportion with post-vaccination titer ≥1:40), serocon-
version rate (SCR; proportion with antibody titer <1:10 at baseline
and with post-vaccination titer of ≥1:40, or pre-vaccination titer
of ≥1:10 and a ≥4-fold post-vaccination increase in titer), and
seroconversion factor (SCF; geometric mean of the ratio between
pre-vaccination and post-vaccination reciprocal HI titers). Subjects
with HI antibody titers of ≥1:10 were considered to be seroposi-
tive. Immunogenicity was  also assessed according to US Center for
Biologics Evaluation and Research (CBER) licensure criteria.
2.2.2.  Reactogenicity and safety
The occurrence and intensity of solicited adverse events (AEs)
was recorded by subjects on diary cards and included local
symptoms (pain, redness, and swelling) and general symptoms
(arthralgia, fatigue, gastrointestinal symptoms, headache, gener-
alised myalgia, shivering, and fever). Unsolicited AEs were assessed
prospectively at each study visit. Injection site reactions were con-
sidered to be related to the vaccine and investigators provided
causality assessments for solicited general symptoms and unso-
licited events.
Reactogenicity and safety outcome measures (secondary objec-
tives) were local and general solicited adverse events during the
7-day post-vaccination period, unsolicited AEs during the 21-day
post-vaccination period, and medically attended events (MAEs) and
serious adverse events (SAEs) during the 6 months study period.
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Non-compliance with  
blood sampling schedule  
6  2  1 
Serological data missing 15   6  3 
ATP immunogenicity 
cohort  
n=1661  
QIV TIV 
Victoria   Yamagata 
n=1246 n=204 n=211 
lot 1  lot 2 lot 3 
n=424 n=425 
Reactogencity cohort 
QIV TIV 
n=1260 
Diary card 
missing 
12 
Yamagata Victoria  
n=42 
Protocol violation  1  -  1 
Non-compliance with  
blood sampling schedule  
1  1  - 
Serological data missing  8  6  5 
TIV 
n=257 n=37 
ATP immunogenicity 
persistence cohort 
n=336  
QIV 
Victoria  Yamagata  
n=44 n=48 
Immunogenicity persistence  
cohort 
n=359 
QIV TIV 
n=267 
d qua
2
a
e
p
m
g
5
w
a
s
r
f
w
e
e
a
m
n
a
p
w
l
tFig. 1. Participant ﬂow. Note: ATP, according-to-protocol; QIV, inactivate
.3. Sample size and statistical analyses
The target sample size for the QIV group was  400 subjects
ssigned to each of the three QIV lots; assuming 6% will be non-
valuable and equivalence among the lots, 375 evaluable subjects
er lot would have 92% power using Bonferroni’s adjustment to
eet the consistency criterion. The target sample size for each TIV
roup was 200 subjects, giving 190 evaluable subjects assuming
% will be non-evaluable. A sample of 1125 for QIV and 190 for TIV
ould have ∼99% power to meet the criteria for superiority against
lternate-lineage B strains, and ∼99% and ∼96% power to demon-
trate non-inferiority against shared A strains and shared B strains,
espectively (each calculation based on a 1-sided, 2-sample t-test
or a difference of means,  ˛ = 2.5%). To fulﬁl CBER licensure criteria
ith ∼99% power using Bonferroni’s adjustment in the QIV group,
ach age stratum (18–64 and ≥65 years) would need at least 562
valuable subjects.
HI  antibody responses were described as the anti-log of the
rithmetic mean of the log-10 transformed inverse geometric
ean titres (GMT). In the lot-to-lot consistency, superiority, and
on-inferiority analyses, GMTs at Day 21 were computed by ﬁtting
n ANCOVA model, including vaccine group as a ﬁxed effect and
re-vaccination antibody titer as a covariate. Lot-to-lot consistency
as based on adjusted GMT  ratios for pairwise comparisons of QIV
ots (lot 1/lot 2, lot 1/lot 3, lot 2/lot 3) for each strain; the pair with
he largest GMT  ratio for each strain was evaluated, and lot-to-lotdrivalent inﬂuenza vaccine; TIV, inactivated trivalent inﬂuenza vaccine.
consistency  was  demonstrated if the 2-sided 95% CI limit was
between 0.67 and 1.5 for all four strains. Superiority of QIV versus
each TIV group for the alternate lineage B strain was demon-
strated if the lower limit of the 2-sided 95% CI on the adjusted
GMT ratio (QIV/TIV) at Day 21 was  ≥1.5 for both comparisons.
Non-inferiority for QIV versus TIV-Vic + TIV-Yam for A strains, and
versus TIV-Vic and TIV-Yam for the B Victoria and B Yamagata
strains, respectively, was  demonstrated if the lower limit of the
2-sided 95% CI on the adjusted GMT  ratio (TIV/QIV) at Day 21 was
≤1.5.
Based on descriptive analyses, immunogenicity parameters
were tabulated with 95% CIs at Day 0, 21, and 180 (sub-cohort),
and CBER licensure criteria for immunogenicity of inﬂuenza vac-
cines were assessed at Day 21 and Day 180; the criteria were
fulﬁlled if the lower limit of the 2-sided 95% CI on the SCR was
≥40% (aged 18–64 years) or ≥30% (aged ≥65 years), and the lower
limit of the 2-sided 95% CI on the SPR was  ≥70% (aged 18–64 years)
and ≥60% (aged ≥65 years) [19]. The immunogenicity analyses
were performed on the according-to-protocol (ATP) immunogenic-
ity cohort including all eligible subjects without protocol deviation
who had serological data available at a given time point. The Day
180 analyses were performed on an ATP sub-cohort (immunogenic-
ity persistence cohort).
The  frequency of solicited and unsolicited adverse events was
tabulated with 95% CIs. Unsolicited AEs were assessed in all vac-
cinated subjects with available diary cards (reactogenicity cohort),
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Table  1
Demographic characteristics at baseline in the total vaccinated cohort.
QIV N = 1272 TIV Victoria lineage N = 213 TIV Yamagata lineage N = 218
Mean age, years (SD; median; range) 50.0 (19.5; 50.0; 18–97) 50.8 (18.5; 51.0; 18–87) 49.6 (19.3; 49.0; 18–91)
Male,  n (%) 491  (38.6) 88  (41.3) 80 (36.7)
Female,  n (%) 781 (61.4) 125 (58.7) 138 (63.3)
Hispanic/Latino ethnicity, n (%) 466 (36.6) 76 (35.7) 79 (36.4)
Not  Hispanic/Latino ethnicity, n (%) 806 (63.4) 137 (64.3) 138 (63.6)
Heritage/race
European  heritage/Caucasian 764 (60.1) 122 (57.3) 129 (59.2)
Arabic/north American heritage/Caucasian 13 (1.0) 4 (1.9) 3 (1.4)
Asian  15 (0.01) 4  (0.01) 4 (0.01)
African  heritage/African American 40 (3.1) 7 (3.3) 6 (2.8)
American  Indian or native Alaskan 5 (0.4) 0 1 (0.5)
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IV, inactivated quadrivalent inﬂuenza vaccine; SD, standard deviation; TIV, inactiv
nd unsolicited adverse events were assessed in all vaccinated sub-
ects (total vaccinated cohort; TVC).
. Results
.1. Subjects
The ﬁrst subject was enrolled on 1 October 2010 and the last
tudy contact was on 21 June 2011. There were 1703 subjects
nrolled, of which 1272 received QIV (423, 424, 425 received lot
, 2, and 3, respectively), and 213 received TIV-Vic and 218 TIV-
am. A total of 1655 subjects completed the study and there were
8 withdrawals of which 6 were associated with an SAE (Fig. 1).
he groups were balanced for baseline demographics and clinical
haracteristics (Table 1). The mean age in the QIV, TIV-Vic, and TIV-
am groups was 50.0 years, 50.8 years, and 49.6 years, respectively.
bout 70% of each group had received seasonal inﬂuenza vaccines
uring one of the previous three seasons.
.2. Immunogenicity
The limits of the two-sided 95% CI for the adjusted GMT  ratios at
ay 21 among the three lots of QIV were between 0.67 and 1.5 for
ach of the four strains, and the criteria for lot-to-lot consistency
ere met.
Superior immunogenicity was shown for QIV versus TIV-Vic
or the Yamagata B strain and versus TIV-Yam for the Victo-
ia B strain; the lower limit of the 95% CI for the GMT  ratio of
IV/TIV-Vic for B/Florida/4/2006 was 1.90 and for Q-QIV/TIV-Yam
or B/Brisbane/60/2008 was 2.11. Non-inferior immunogenicity
as shown for QIV versus each TIV for the shared vaccine strains
Table 2).
In  the QIV group, the lower limits of 95% CI for SPR were ≥70% or
60% for all four vaccine strains in the 18–64 and ≥65 years strata,
espectively, fulﬁlling CBER criteria (Fig. 2). The 95% CI for the SCR
as ≥40% for all four vaccine strains in the 18–64 years stratum,
able 2
on-inferiority of QIV versus TIVs against shared strains according to HI-assay based GM
Vaccine antigen TIV-Vic + TIV-Yam 
N Adjusted GMT  
A/California/7/2009 (H1N1) 414 160.0 
A/Victoria/210/2009 (H3N3) 415 147.6 
TIV-Vic 
B/Brisbane/60/2008 (Victoria lineage) 203 133.0 
TIV-Yam 
B/Florida/4/2006 (Yamagata lineage) 211 311.7 
Non-inferiority was  demonstrated if the lower limit of the 95% CI was ≤1.5.
TP,  according-to-protocol; CI, conﬁdence interval; GMT, geometric mean titer; HI, Hem
ineage B strain; Yam, Yamagata lineage B strain; QIV, inactivated quadrivalent inﬂuenza76 (35.7) 75 (34.4)
rivalent inﬂuenza vaccine.
and  ≥30% for A/H1N1, A/H3N2, and the Yamagata lineage B strain
in the ≥65 years stratum, fulﬁlling CBER criteria (Fig. 2). The SCR
for the Victoria lineage B strain in the ≥65 years stratum was 31.2%
(95% CI: 26.7, 36.0).
QIV,  TIV-Vic, and TIV-Yam were highly immunogenic against
each vaccine strain in each group overall at Day 21. At Day 180,
seropositivity rates were 88.3–100% in the QIV group, 97.3–100%
in the TIV-Vic group and 83.3–100% in the TIV-Yam group
(Table 3).
3.3.  Reactogenicity and safety
Injection site pain was  the most frequency local solicited symp-
tom and was  reported by 59.5% (750/1260) of the QIV group, and
44.7% (93/208) of the TIV-Vic, and 41.2% (89/216) of the TIV-Yam
group; grade 3 pain was  reported by 1.7%, 1.0% and 1.4% of the
QIV, TIV-Vic, and TIV-Yam groups, respectively (Fig. 3). Other local
events were uncommon (Fig. 3). Fatigue, headache, and muscle
aches were the most frequently reported solicited general symp-
toms in all groups (Fig. 3). Fatigue was reported by 21.5% (271/1260)
of the QIV group, and 21.6% (45/208) and 17.1% (37/216) of the
TIV-Vic and TIV-Yam groups, respectively. The incidence of grade
3 solicited general symptoms was  <1.3% in each group.
During the 21-day post-vaccination period, at least one unso-
licited AE was  reported by 19.2% (244/1272) of the QIV group,
and 22.5% (48/213) and 23.4% (51/218) of the TIV-Vic and TIV-
Yam groups, respectively. The most frequent unsolicited AEs were
oropharyngeal pain, cough, and nasopharyngitis, occurring at a fre-
quency of 1.7–2.8%. Grade 3 unsolicited AEs were reported by 26
(2.0%), 6 (2.8%), and 7 (3.2%) of the QIV, TIV-Vic and TIV-Yam groups,
respectively.
During the 6-month follow-up, at least one MAE  was  reported by
25.9% (330/1272) of the QIV group, and 23.9% (51/213) and 29.4%
(64/218) of the TIV-Vic and TIV-Yam, respectively. The most fre-
quent MAEs were sinusitis (2.1–3.2%) and upper respiratory tract
infection (0.9–2.3%). During the 6-month follow-up, at least one
Ts at Day 21 in the ATP immunogenicity cohort.
QIV TIV-Vic + TIV-Yam/QIV
n Adjusted GMT  Adjusted GMT  ratio (95% CI)†
1238 205.1 0.78 (0.68, 0.90)
1237 124.2 1.19 (1.05, 1.35)
QIV TIV-Vic/QIV
1240 177.2 0.75 (0.65, 0.87)
QIV TIV-Yam/QIV
1241 396.2 0.79 (0.69, 0.90)
agglutination inhibition; TIV, inactivated trivalent inﬂuenza vaccine; Vic, Victoria
 vaccine.
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AE was reported by 2.8% (35/1272) of the QIV group, and 1.4%
3/213) and 3.2% (7/218) of the TIV-Vic and TIV-Yam groups, respec-
ively (Supplementary Table 1). None of the SAEs were considered
o be vaccine related.
.  Discussion
This Phase III, randomized, double-blind study of healthy adults
ged ≥18 years showed that QIV was immunologically superior
ersus TIV for the alternate-lineage B strain, and was non-inferior
or the inﬂuenza strains shared in the QIV and TIVs. HI antibody
esponses were also shown to be consistent between three lots of
IV, thus demonstrating manufacturing consistency of the candi-
ate vaccine. Our results show that in people aged ≥18 years, QIV
ffers improved immunogenicity against the additional B strain
ithout affecting antibody responses to existing strains compared
ith conventional TIVs; therefore, our study supports a switch
rom conventional TIV to QIV with the aim of improving protection
gainst inﬂuenza B disease.The  immunogenicity and safety ﬁndings reported for this
IV which was manufactured in Canada are consistent with a
revious report of an inactivated QIV produced by the same
ompany using a different process at facilities in Germany [16]., or pre-vaccination titer of ≥1:10 and a ≥4-fold post-vaccination increase in titer.
The  results add to the growing evidence in both children and
adults which shows that live attenuated and inactivated QIVs
provide similar immune responses against shared vaccine strains
versus TIV with added protection against the additional B strain
[12–17].
We showed that each of the vaccines elicited strong HI
antibody responses against the A/H1N1 and A/H3N2 vaccine
strains, and against B/Brisbane/60/2008 (Victoria) and/or against
B/Florida/4/2006 (Yamagata). SCRs and SPRs against each vaccine
strain were considered to be high, and immune responses were
slightly stronger against inﬂuenza A than inﬂuenza B strains with
QIV and both TIVs. The persistence of antibody responses was
assessed six months after vaccination in a sub-cohort of subjects,
and whereas immune responses decreased at 6 months in each
vaccine group relative to those measured at day 21 after vaccina-
tion, they remain notably increased above baseline levels. In the
QIV group, antibody persistence at 6 months appeared to be more
robust against the inﬂuenza B strains with SPRs of 94.9% and 99.6%
against B/Victoria and B/Yamagata, respectively, compared with
SPRs of 66.5% and 64.6% against A/H1N1 and A/H3N2, respectively.
Antibody levels were decreased against the inﬂuenza A strains at
6 months post-vaccination, and the clinical signiﬁcance of this is
uncertain.
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Table  3
Descriptive immunogenicity based on HI assays in the QIV and TIV groups in the ATP immunogenicity persistence cohort.
Seropositive GMT  SCR SPR
n/N (%; 95% CI) N; Value (95% CI) n/N (%; 95% CI) n/N (%; 95% CI)
A/California/7/2009 (H1N1)
QIV 0  142/257 (55.3; 48.9, 61.4) 257; 16.4 (13.9, 19.2) – 91/257 (35.4; 29.6, 41.6)
21  248/257 (96.5; 93.5, 98.4) 257; 173.5 (146.8, 205.0) 184/257 (71.6; 65.7, 77.0) 236/257 (91.8; 87.8, 94.9)
180  227/257 (88.3; 83.8, 92.0) 257; 51.7 (43.9, 61.1) 102/257 (39.7; 33.7, 46.0) 171/257 (66.5; 60.4, 72.3)
TIV-
Vic
0  23/37 (62.2; 44.8, 77.5) 37; 20.4 (12.5, 33.2) – 15/37 (40.5; 24.8, 57.9)
21  36/37 (97.3; 85.8, 99.9) 37; 211.9 (132.4, 339.0) 25/37 (67.6; 50.2, 82.0) 33/37 (89.2; 74.6, 97.0)
180  36/37 (97.3; 85.8, 99.9) 37; 74.2 (48.0, 114.7) 14/37 (37.8; 22.5, 55.2) 26/37 (70.3; 53.0, 84.1)
TIV-
Yam
0  23/42 (54.8; 38.7, 70.2) 42; 13.7 (9.3, 20.1) – 8/42 (19.0; 8.6, 34.1)
21  38/42 (90.5; 77.4, 97.3) 42; 126.0 (77.0, 206.3) 27/42 (64.3; 48.0, 78.4) 35/42 (83.3; 68.6, 93.0)
180  35/42 (83.3; 68.6, 93.0) 42; 45.3 (28.9, 71.0) 18/42 (42.9; 27.7, 59.0) 26/42 (61.9; 45.6, 76.4)
A/Victoria/210/2009 (H3N2)
QIV 0  159/257 (61.9; 55.6, 67.8) 257; 16.7 (14.4, 19.4) – 81/257 (31.5; 25.9, 37.6)
21  247/256 (96.5; 93.4, 98.4) 256; 121.4 (105.1, 140.2) 172/256 (67.2; 61.1, 72.9) 234/256 (91.4; 87.3, 94.5)
180  241/257 (93.8; 90.1, 96.4) 257; 42.1 (37.1, 47.9) 75/257 (29.2; 23.7, 35.2) 166/257 (64.6; 58.4, 70.4)
TIV-
Vic
0  22/37 (59.5; 42.1, 75.2) 37; 14.4 (9.8, 21.2) – 9/37 (24.3; 11.8, 41.2)
21  37/37 (100; 90.5, 100) 37; 166.0 (108.9, 253.2) 27/37 (73.0; 55.9, 86.2) 35/37 (94.6; 81.8, 99.3)
180  36/37 (97.3; 85.8, 99.9) 37; 46.4 (33.9, 63.7) 17/37 (45.9; 29.5, 63.10) 25/37 (67.6; 50.2, 82.0)
TIV-
Yam
0  23/42 (54.8; 38.7, 70.2) 42; 14.6 (10.2, 20.8) – 12/42 (28.6; 15.7, 44.6)
21  42/42 (100; 91.6, 100) 42; 166.7(119.2, 233.3) 32/42 (76.2; 60.5, 87.9) 41/42 (97.6; 87.4, 99.9)
180  42/42 (100; 91.6, 100) 42; 61.9 (44.0, 87.1) 19/42 (45.2; 29.8, 61.3) 33/42 (78.6; 63.2, 89.7)
B/Brisbane/60/2008 (Victoria)
QIV 0  207/257 (80.5; 75.2, 85.2) 257; 31.1 (26.8, 36.2) – 139/257 (54.1; 47.8, 60.3)
21  257/257 (100; 98.6, 100) 257; 179.0 (158.4, 202.2) 136/257 (52.9; 46.6, 59.2) 252/257 (98.1; 95.5, 99.4)
180  256/257 (99.6; 97.9, 100) 257; 120.1 (106.8, 134.9) 103/257 (40.1; 34.0, 46.3) 244/257 (94.9; 91.5, 97.3)
TIV-
Vic
0  31/37 (83.8; 68.0, 93.8) 37; 36.8 (24.8, 54.5) – 24/37 (64.9; 47.5, 79.8)
21  37/37 (100; 90.5, 100) 37; 137.7 (106.0, 179.0) 15/37 (40.5; 24.8, 57.9) 36/37 (97.3; 85.8, 99.9)
180  37/37 (100; 90.5, 100) 37; 114.2 (92.9, 140.4) 13/37 (35.1; 20.2, 52.5) 37/37 (100; 90.5, 100)
TIV-
Yam
0  32/42 (76.2; 60.5, 87.9) 42; 23.8 (16.7, 33.9) – 19/42 (45.2; 29.8, 61.3)
21  39/42 (92.9; 80.5, 98.5) 42; 62.9 (43.6, 90.8) 11/42 (26.2; 13.9, 42.0) 33/42 (78.6; 63.2, 89.7)
180  41/42 (97.6; 87.4, 99.9) 42; 68.4 (49.4, 94.6) 11/42 (26.2; 13.9, 42.0) 33/42 (78.6; 63.2, 89.7)
B/Florida/4/2006 (Yamagata)
QIV 0  240/257 (93.4; 89.6, 96.1) 257; 77.3 (66.5, 89.9) – 208/257 (80.9; 75.6, 85.5)
21  257/257 (100; 98.6, 100) 257; 399.2 (355.8, 447.9) 135/257 (52.5; 46.2, 58.8 257/257 (100; 98.6, 100)
180  257/257 (100; 98.6, 100) 257 253.1 (226.4, 282.9) 100/257 (38.9; 32.9, 45.2) 256/257 (99.6; 97.9, 100)
TIV-
Vic
0  36/37 (97.3; 85.8, 99.9) 37; 92.9 (64.6, 133.7) – 32/37 (86.5; 71.2, 95.5)
21  37/37 (100; 90.5, 100) 37; 194.8 (153.5, 247.2) 8/37 (21.6; 9.8, 38.2) 37/37 (100; 90.5, 100)
180  37/37 (100; 90.5, 100) 37; 167.8 (129.2, 217.8) 5/37 (13.5; 4.5, 28.8) 37/37 (100; 90.5, 100)
TIV-
Yam
0  40/42 (95.2; 83.8, 99.4) 42; 68.4 (47.4, 98.7) – 33/42 (78.6; 63.2, 89.7)
21  42/42 (100; 91.6, 100) 42; 275.8 (194.1, 392.0) 20/42 (47.6; 32.0, 63.6) 41/42 (97.6; 87.4, 99.9)
180  42/42 (100; 91.6, 100) 42; 239.6 (171.9, 334.1) 15/42 (35.7; 21.6, 52.0) 40/42 (95.2; 83.8, 99.4)
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Descriptive analyses were also performed to further assess the
mmunogenicity of QIV according to age. The median age was 50.0
ears (18–91 years) overall, with an equal distribution of subjects
ged 18–64 years versus ≥65 years in each group. In subjects aged
8–64 years in the QIV group, the vaccine fulﬁlled CBER licen-
ure criteria for immunogenicity against all four vaccine strains,
ut in the ≥65 years stratum, the criteria was fulﬁlled for A/H1N1,
/H3N2, and inﬂuenza B/Victoria, but the SCR criterion for inﬂuenza
/Yamagata was not met. However, the proportion of subjects aged
65 years who had pre-vaccination antibody titers of ≥1:40 against
he strain from the B/Yamagata lineage was relatively high (87.4%),
ompared with the pre-vaccination SPR in the younger stratum
77.0%). In two of the three preceding inﬂuenza seasons, a Yam-
gata lineage B strain was recommended for use in TIVs for annual
accination in people aged ≥65 years in the Northern Hemisphere,
nd this may  have accounted for the relatively high baseline anti-
ody levels in older subjects in our study. A tabulation of SCR by
rior inﬂuenza vaccination status in the ≥65 years stratum in our
tudy showed that the SCR met  the CBER criterion in 34 subjects
ithout inﬂuenza vaccination in the past three seasons, whereas in
63 subjects who had received inﬂuenza vaccine in the past threeagglutination inhibition; TIV-Vic, inactivated trivalent inﬂuenza vaccine Victoria
in; QIV, inactivated quadrivalent inﬂuenza vaccine.
seasons,  licensure criteria against the Yamagata lineage B strain
were not met  (data not shown).
The safety analysis in our study showed that the most frequent
injection site reaction was  pain (>41% of subjects in each vac-
cine group) and the most frequent solicited general events were
headache and muscle ache (∼20% of each vaccine group). During
the 6-month follow-up, the rate of SAEs was  low in all vaccine
groups, and no SAE was  considered to be vaccine-related. Overall,
the reactogenicity and safety proﬁle of QIV was consistent with the
established proﬁle of seasonal inﬂuenza vaccines, suggesting that
inclusion of an additional 15 g of antigen in the candidate QIV did
not compromise safety compared with TIV.
Although this study provides evidence of the viability of the can-
didate QIV, the limitation of the trial is that immunogenicity is a
surrogate of protection; further studies are needed to evaluate if
covering both inﬂuenza B lineages improves vaccine efﬁcacy, and
to establish if QIV reduces the burden of inﬂuenza versus TIV, as
previously suggested by modelling studies [9]. Natural exposure to
inﬂuenza viruses was a potential confounding factor as enrollment
may have coincided with increased inﬂuenza activity. In Mexico,
the inﬂuenza season started in July 2010, peaked in late-December
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Fig. 3. Local (A) and general (B) solicited adverse events during the 7-day post-
vaccination  periods in the reactogenicity cohort. Note: QIV, inactivated quadrivalent
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train; TIV-Yam, inactivated trivalent inﬂuenza vaccine Yamagata lineage B strain;
I, conﬁdence interval.
nd was over by January 2011, in Canada the season peaked in
arly January 2011, and in the US, the season peaked in mid-
ebruary 2011 [20]. Subjects were enrolled in early October 2010
nd enrollment continued into mid-December, meaning that in the
S and Canada, the majority of blood samples were taken before
eak-season, thus limiting the impact of natural exposure. The
ub-cohort in Mexico may  have been exposed to natural inﬂuenza
irus infection between vaccination and 21-day blood sampling,
lthough such exposure is likely to have been limited to about 5%
f the sub-cohort. In addition, in Mexico, transmission was  nearly
ntirely associated with A/H3N2, and in the US and Canada, A/H3N2
as also the predominant virus; pre-vaccination antibody titers to
/H3N2 were low (GMTs 13.9–16.0) and did not suggest discernible
mmune responses to natural exposure [20]. Furthermore, because
his was a randomized, controlled study, any boost to the immune
esponse by natural infection is expected to be similar among the
reatment arms and, therefore, the analysis of the conﬁrmatory
bjectives would not have been confounded. Indeed, there was no
vidence to suggest that the study was limited by this phenomenon.
In conclusion, the results conﬁrm the manufacturing consis-
ency of the candidate QIV, and shows that compared with TIV, QIV
rovides superior immunogenicity against the additional B strain
nd non-inferior immunogenicity against the shared strains.
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